153 related articles for article (PubMed ID: 18395138)
61. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
62. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
63. Anderson-Fabry disease and the heart.
O'Mahony C; Elliott P
Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
[TBL] [Abstract][Full Text] [Related]
64. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
del Toro N; Milán JA; Palma A
Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
[No Abstract] [Full Text] [Related]
65. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
66. Kidney transplantation in patients with Fabry disease.
Cybulla M; Walter KN; Schwarting A; Divito R; Feriozzi S; Sunder-Plassmann G;
Transpl Int; 2009 Apr; 22(4):475-81. PubMed ID: 19207191
[TBL] [Abstract][Full Text] [Related]
67. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
68. Fabry disease--a diagnostic and therapeutic problem.
Strujić BJ; Jeren T
Ren Fail; 2005; 27(6):783-6. PubMed ID: 16350834
[TBL] [Abstract][Full Text] [Related]
69. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
70. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
Ramaswami U
Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
[TBL] [Abstract][Full Text] [Related]
71. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
[TBL] [Abstract][Full Text] [Related]
72. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy.
Koh S; Sakai N; Maeda N; Nishida K
Acta Ophthalmol; 2018 Mar; 96(2):e255-e256. PubMed ID: 28834375
[No Abstract] [Full Text] [Related]
73. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
[No Abstract] [Full Text] [Related]
74. Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease.
Masarone D; Duro G; Dellegrottaglie S; Colomba P; Rubino M; Cirillo A; Pisani A; Caiazza M; Elliott PM; Calabrò P; Pacileo G; Limongelli G
Future Cardiol; 2017 Nov; 13(6):521-527. PubMed ID: 28936893
[TBL] [Abstract][Full Text] [Related]
75. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue.
Frustaci A; Chimenti C
Circulation; 2007 Sep; 116(12):e350-1. PubMed ID: 17875975
[No Abstract] [Full Text] [Related]
76. Diagnosing Fabry disease--delays and difficulties within discordant siblings.
Brady M; Montgomery E; Brennan P; Mohindra R; Sayer JA
QJM; 2015 Jul; 108(7):585-90. PubMed ID: 23378663
[No Abstract] [Full Text] [Related]
77. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
[No Abstract] [Full Text] [Related]
78. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.
Roddy TP; Nelson BC; Sung CC; Araghi S; Wilkens D; Zhang XK; Thomas JJ; Richards SM
Clin Chem; 2005 Jan; 51(1):237-40. PubMed ID: 15514097
[No Abstract] [Full Text] [Related]
79. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.
Linhart A; Kampmann C; Zamorano JL; Sunder-Plassmann G; Beck M; Mehta A; Elliott PM;
Eur Heart J; 2007 May; 28(10):1228-35. PubMed ID: 17483538
[TBL] [Abstract][Full Text] [Related]
80. [Fabry disease].
Jakubowska E; Ryba M; Hruby Z
Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
